Analysts fell to the sidelines weighing in on Pacira Pharmaceuticals (PCRX) and Marinus (MRNS) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Pacira Pharmaceuticals (PCRX)
Pacira Pharmaceuticals received a Hold rating and a $38 price target from Mizuho Securities analyst Irina Rivkind Koffler today. The company’s shares closed on Friday at $46.81.
Rivkind Koffler observed:
“We arrive at a revised $38 PT (from $29) by raising our revenue forecast and terminal growth rate, but still remain concerned about the longer-term outlook for the company.”
According to TipRanks.com, Koffler is a 3-star analyst with an average return of 2.7% and a 38.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $53.22, which is a 13.7% upside from current levels. In a report issued on May 2, Stifel Nicolaus also upgraded the stock to Hold with a $45 price target.
See today’s analyst top recommended stocks >>
Marinus (MRNS)
In a report released today, Difei Yang from Mizuho Securities maintained a Hold rating on Marinus, with a price target of $5. The company’s shares closed on Friday at $4.66.
Yang said:
“We believe the key value driver for the company remains the postpartum depression (PPD) program and upcoming Phase 2 readouts, which are now expected in 3Q19 (vs. previously planned 2Q19) due to an increase in the study size. We are not concerned by the delay; a 4-6 week delay in clinical development is common. Marinus also hosted an analyst day on 04/30/19 to provide an overview of the refractory status epilepticus (RSE) indication. Data from this signal-seeking trial could be available in 3Q19.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.6% and a 42.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $16.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
